Lybrate Raises $10.2 million from Ratan Tata and others
NEW DELHI: It seems like a good year for internet based- healthcare startups.
Healthcare communication and delivery startup Lybrate on Wednesday announced that it has received a series A funding of $10.2 million from Ratan Tata, Tiger Global and Nexus Venture Partners.
The startup, which enables patients to anonymously communicate with doctors via a mobile app or online from anywhere and anytime, plans to utilize the funds for product development, recruitment and augmenting technology and scale operations, it said in a statement.
It seems like the investors have strong faith in the business model of Lybrate. Tiger Global partner Lee Fixel was quoted as saying: "Lybrate's concept is ground-breaking. We believe it has the potential to revolutionize healthcare delivery in India and script the future of the healthcare industry with its model."
Founded in 2013 by Saurabh Arora, a former Facebook employee in the US, Lybrate aims to address the fundamental healthcare delivery problems in India, inaccessibility and self-medication, the statement added.
"We ignore our health and rush to take a call at delayed stages when the disease has progressed to serious levels. The tendency to consult chemists because of time constraint and inertia to visit a doctor is rampant and leads to risky behaviour of self-medication," said Arora.
The ability to remain anonymous enables people to talk health problems ranging from sexual health, women's health, psychological problems and depression, he added.
Since the launch of Lybrate App in January 2015, it was downloaded 500,000 times and over 100,000 patients are visiting the platform everyday where 80,000 doctors from various specialties across India are connected, the statement said.
Lybrate is scrutinizing every doctor's license and credentials before allowing them onto the platform, it added.
The startup, which enables patients to anonymously communicate with doctors via a mobile app or online from anywhere and anytime, plans to utilize the funds for product development, recruitment and augmenting technology and scale operations, it said in a statement.
It seems like the investors have strong faith in the business model of Lybrate. Tiger Global partner Lee Fixel was quoted as saying: "Lybrate's concept is ground-breaking. We believe it has the potential to revolutionize healthcare delivery in India and script the future of the healthcare industry with its model."
Founded in 2013 by Saurabh Arora, a former Facebook employee in the US, Lybrate aims to address the fundamental healthcare delivery problems in India, inaccessibility and self-medication, the statement added.
"We ignore our health and rush to take a call at delayed stages when the disease has progressed to serious levels. The tendency to consult chemists because of time constraint and inertia to visit a doctor is rampant and leads to risky behaviour of self-medication," said Arora.
The ability to remain anonymous enables people to talk health problems ranging from sexual health, women's health, psychological problems and depression, he added.
Since the launch of Lybrate App in January 2015, it was downloaded 500,000 times and over 100,000 patients are visiting the platform everyday where 80,000 doctors from various specialties across India are connected, the statement said.
Lybrate is scrutinizing every doctor's license and credentials before allowing them onto the platform, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.